Archive for February 2022
Update to COVID-19 Treatment Guidelines: Changes Affecting People with HIV
February 7, 2022: The COVID-19 Treatment Guidelines Panel (the Panel) has published a revised version of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. The Panel periodically publishes statements that provide up-to-date guidance for clinicians on various aspects of COVID-19 treatment. During this update, the information and recommendations from several recently published statements were incorporated into the…
Read MoreUpdates to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV
February 17, 2022: The Panel updated the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Highlights from the updated section are summarized below: Mycobacterium tuberculosis Updated references and rationales. Updated drug–drug interactions. Recommended short-course, rifamycin-based, latent tuberculosis infection (LTBI) treatment regimens (3HP and 3HR) over longer isoniazid monotherapy. Clarified that, for the…
Read MoreFDA Approves First Injectable Treatment for #HIV Pre-Exposure Prevention (PrEP)
On December 10, 2021, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pounds) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV. Apretude is given first as two initiation injections administered one month apart, and then every…
Read MoreUpdates to Perinatal HIV Clinical Guidelines
January 5, 2022: The Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission recently updated several sections of the Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. The following sections were among those updated: Maternal HIV Testing and Identification of Perinatal…
Read MoreUpdates to the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV
This notice updates and corrects an announcement on this subject sent January 20, 2022. The Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel) updated the following sections of the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Highlights are summarized below: Early (Acute and Recent) HIV Infection…
Read More